IFNGR1 and neoplasm: When RSL3 or erastin was combined with IFN-γ, lipid ROS in tumor cells was relatively higher than in the single-treatment groups, while the synergistic effect was low in IFN-γR1-deficient B16 cells; the tumor-burdened experiment in vivo led to the same conclusion.